At Guerbet, we build lasting relationships so that we enable people to live better. This is our Purpose. We place human cooperation at the heart of our relationships and actions.
We are a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging.
A pioneer since 95 years in the field of contrast media, we are a team of over 2,600 people globally, continuously innovating with 10% of revenue dedicated to Research & Development across four centers in France, Israel and the United States.
1926
Served areaWorldwide
Headcount2,730
HeadquartersZone Paris Nord II 15 Rue des Vanesses, 93420 Villepinte – France
Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
---|---|---|---|---|
Assets | N/A | 945,707,000.00 | 1,000,833,000.00 | 939,643,000.00 |
Noncurrent Assets | N/A | 477,147,000.00 | 505,379,000.00 | 429,970,000.00 |
Property Plant And Equipment | N/A | 261,294,000.00 | 274,046,000.00 | 286,119,000.00 |
Intangible Assets Other Than Goodwill | N/A | 188,267,000.00 | 188,618,000.00 | N/A |
Deferred Tax Assets | N/A | 11,046,000.00 | 19,419,000.00 | 16,653,000.00 |
Other Noncurrent Financial Assets | N/A | 16,540,000.00 | 23,295,000.00 | 29,273,000.00 |
Current Assets | N/A | 468,559,000.00 | 495,454,000.00 | 509,673,000.00 |
Inventories | N/A | 204,587,000.00 | 201,952,000.00 | 272,496,000.00 |
Other Current Financial Assets | N/A | 56,220,000.00 | 59,000,000.00 | 63,955,000.00 |
Cash and cash equivalents | N/A | 96,713,000.00 | 115,728,000.00 | 41,683,000.00 |
Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | N/A | N/A | 0.00 | 10,300,000.00 |
Equity And Liabilities | N/A | 945,707,000.00 | 1,000,833,000.00 | 939,643,000.00 |
Equity | 389,192,000.00 | 367,754,000.00 | 405,092,000.00 | 379,570,000.00 |
Issued Capital | N/A | 12,603,000.00 | 12,641,000.00 | 12,641,000.00 |
Retained Earnings Profit Loss For Reporting Period | N/A | N/A | 32,637,000.00 | -41,116,000.00 |
Other Reserves | N/A | 397,461,000.00 | 408,234,000.00 | 444,835,000.00 |
Equity Attributable To Owners Of Parent | N/A | 364,305,000.00 | 405,092,000.00 | 379,570,000.00 |
Noncurrent Liabilities | N/A | 377,736,000.00 | 358,873,000.00 | 320,453,000.00 |
Noncurrent Provisions | N/A | 40,289,000.00 | 41,988,000.00 | 32,150,000.00 |
Deferred Tax Liabilities | N/A | 14,766,000.00 | 15,246,000.00 | 9,872,000.00 |
Other Noncurrent Financial Liabilities | N/A | 4,305,000.00 | 1,947,000.00 | 0.00 |
Current Liabilities | N/A | 200,216,000.00 | 236,869,000.00 | 239,620,000.00 |
Other Shortterm Provisions | N/A | N/A | 9,774,000.00 | 13,912,000.00 |
Trade And Other Current Payables | N/A | 64,413,000.00 | 81,021,000.00 | 103,711,000.00 |
Current Tax Liabilities Current | N/A | 8,086,000.00 | 15,011,000.00 | 19,366,000.00 |
Liabilities Included In Disposal Groups Classified As Held For Sale | N/A | N/A | 0.00 | 0.00 |
Other Current Liabilities | N/A | 88,438,000.00 | 97,217,000.00 | 69,021,000.00 |
Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
---|---|---|---|
Revenue | 712,295,000.00 | 732,071,000.00 | 753,275,000.00 |
Revenue From Royalties | 0.00 | 0.00 | 8,001,000.00 |
Interest Income On Cash And Cash Equivalents | 83,000.00 | 59,000.00 | 34,000.00 |
Other Income | 5,397,000.00 | 4,941,000.00 | 8,879,000.00 |
Raw Materials And Consumables Used | 166,552,000.00 | 190,934,000.00 | 180,424,000.00 |
Services Expense | 203,975,000.00 | 195,565,000.00 | 232,585,000.00 |
Employee Benefits Expense | 236,500,000.00 | 232,789,000.00 | 240,664,000.00 |
Depreciation And Amortisation Expense | 59,649,000.00 | 55,945,000.00 | 119,625,000.00 |
Tax Expense Other Than Income Tax Expense | 15,852,000.00 | 13,459,000.00 | 14,992,000.00 |
Profit Loss From Operating Activities | 41,872,000.00 | 38,685,000.00 | -18,160,000.00 |
Income Tax Expense Continuing Operations | 4,008,000.00 | -3,664,000.00 | 12,744,000.00 |
Profit (loss) | 18,240,000.00 | 32,637,000.00 | -41,116,000.00 |
Profit Loss Attributable To Owners Of Parent | 18,240,000.00 | 32,637,000.00 | -41,116,000.00 |
Line item in (eur) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
---|---|---|---|
Profit (loss) | 18,240,000.00 | 32,637,000.00 | -41,116,000.00 |
Adjustments For Income Tax Expense | 4,008,000.00 | -3,664,000.00 | 12,744,000.00 |
Adjustments For Decrease Increase In Inventories | 17,383,000.00 | 4,578,000.00 | -68,228,000.00 |
Adjustments For Depreciation And Amortisation Expense | 57,741,000.00 | 58,320,000.00 | 123,134,000.00 |
Adjustments For Provisions | 1,379,000.00 | 8,316,000.00 | 382,000.00 |
Adjustments For Sharebased Payments | -1,307,000.00 | 610,000.00 | -399,000.00 |
Adjustments For Fair Value Gains Losses | -168,000.00 | 443,000.00 | -1,358,000.00 |
Adjustments For Losses Gains On Disposal Of Noncurrent Assets | 5,367,000.00 | 286,000.00 | 2,273,000.00 |
Cash Flows From Used In Operating Activities | 120,432,000.00 | 115,973,000.00 | 30,441,000.00 |
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | 1,644,000.00 | 840,000.00 | 1,194,000.00 |
Purchase Of Property Plant And Equipment Classified As Investing Activities | 39,792,000.00 | 37,500,000.00 | 43,835,000.00 |
Proceeds From Sales Of Intangible Assets Classified As Investing Activities | 1,038,000.00 | 720,000.00 | 720,000.00 |
Purchase Of Intangible Assets Classified As Investing Activities | 19,890,000.00 | 11,431,000.00 | 6,688,000.00 |
Cash Flows From Used In Investing Activities | -57,288,000.00 | -52,243,000.00 | -55,398,000.00 |
Proceeds From Issuing Shares | 100,000.00 | 592,000.00 | 0.00 |
Proceeds From Borrowings Classified As Financing Activities | 7,337,000.00 | 6,581,000.00 | 2,398,000.00 |
Repayments Of Borrowings Classified As Financing Activities | 40,607,000.00 | 34,392,000.00 | 35,659,000.00 |
Dividends Paid Classified As Financing Activities | 8,825,000.00 | 8,814,000.00 | 10,733,000.00 |
Interest Paid Classified As Financing Activities | 4,890,000.00 | 5,250,000.00 | 4,552,000.00 |
Cash Flows From Used In Financing Activities | -46,887,000.00 | -41,283,000.00 | -48,546,000.00 |
Effect Of Exchange Rate Changes On Cash And Cash Equivalents | -3,699,000.00 | 68,000.00 | -620,000.00 |
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | 12,560,000.00 | 22,515,000.00 | -74,122,000.00 |
Cash and cash equivalents | 96,713,000.00 | 115,728,000.00 | 41,683,000.00 |
Please note that some sums might not add up.
Date | Trading entity / Person | Association | Trade type | Volume |
---|---|---|---|---|
04.05.23 | None | Other | Buy | EUR 4,938.00 |
FR0000032526
LEI969500WV1U1WQ059L135
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.